Abstract
Background and Aims: Fibroblast growth factor 21 (FGF21), a key regulator of energy metabolism, is currently evaluated in humans for treatment of cardiometabolic disease. However, its role in atherogenesis remains elusive. Therefore, the aim of this study is to investigate the therapeutic effects of FGF21 on atherosclerosis and the underlying mechanisms in APOE*3-Leiden.CETP mice, a well-established model for human-like lipoprotein metabolism.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
